These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 27231869)

  • 1. Recent Advances and Future Needs in Interstitial Lung Diseases.
    Jones MG; Richeldi L
    Semin Respir Crit Care Med; 2016 Jun; 37(3):477-84. PubMed ID: 27231869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial Lung Disease: A Review.
    Maher TM
    JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic advances in idiopathic pulmonary fibrosis.
    Fraser E; Hoyles RK
    Clin Med (Lond); 2016 Feb; 16(1):42-51. PubMed ID: 26833513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving pharmacotherapy of pulmonary fibrosis.
    Lota HK; Wells AU
    Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).
    Kreuter M; Wälscher J; Behr J
    Curr Opin Pulm Med; 2017 Sep; 23(5):418-425. PubMed ID: 28622199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.
    Collins BF; Raghu G
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31578210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in the management of idiopathic pulmonary fibrosis.
    Drug Ther Bull; 2015 Jul; 53(7):78-81. PubMed ID: 26159700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update in diffuse parenchymal lung disease, 2013.
    Rosas IO; Kaminski N
    Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic pulmonary fibrosis.
    Koudstaal T; Wijsenbeek MS
    Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis.
    Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M
    Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
    Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
    Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
    Spagnolo P; Maher TM; Richeldi L
    Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.